• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黑色素瘤及其他癌症中蛋白激酶信号通路的建模

Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers.

作者信息

Kunz Manfred, Vera Julio

机构信息

Department of Dermatology, Venereology and Allergology, University of Leipzig, Philipp-Rosenthal-Str. 23, 04103 Leipzig, Germany.

Laboratory of Systems Tumor Immunology, Department of Dermatology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstr. 14, 91052 Erlangen, Germany.

出版信息

Cancers (Basel). 2019 Apr 3;11(4):465. doi: 10.3390/cancers11040465.

DOI:10.3390/cancers11040465
PMID:30987166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6520749/
Abstract

Melanoma is a highly aggressive tumor with a strong dependence on intracellular signaling pathways. Almost half of all melanomas are driven by mutations in the v-Raf murine sarcoma viral oncogene homolog B () with V600E being the most prevalent mutation. Recently developed targeted treatment directed against mutant BRAF and downstream mitogen-activated protein kinase (MAPK) MAP2K1 (also termed MEK1) have improved overall survival of melanoma patients. However, the MAPK signaling pathway is far more complex than a single chain of consecutively activated MAPK enzymes and it contains nested-, inherent feedback mechanisms, crosstalk with other signaling pathways, epigenetic regulatory mechanisms, and interacting small non-coding RNAs. A more complete understanding of this pathway is needed to better understand melanoma development and mechanisms of treatment resistance. Network reconstruction, analysis, and modelling under the systems biology paradigm have been used recently in different malignant tumors including melanoma to analyze and integrate 'omics' data, formulate mechanistic hypotheses on tumorigenesis, assess and personalize anticancer therapy, and propose new drug targets. Here we review the current knowledge of network modelling approaches in cancer with a special emphasis on melanoma.

摘要

黑色素瘤是一种极具侵袭性的肿瘤,对细胞内信号通路有很强的依赖性。几乎一半的黑色素瘤是由v-Raf鼠肉瘤病毒癌基因同源物B()的突变驱动的,其中V600E是最常见的突变。最近开发的针对突变型BRAF和下游丝裂原活化蛋白激酶(MAPK)MAP2K1(也称为MEK1)的靶向治疗提高了黑色素瘤患者的总体生存率。然而,MAPK信号通路远比单一的连续激活的MAPK酶链复杂,它包含嵌套的、内在的反馈机制、与其他信号通路的串扰、表观遗传调控机制以及相互作用的小非编码RNA。需要更全面地了解这条通路,以更好地理解黑色素瘤的发展和治疗耐药机制。最近,在系统生物学范式下的网络重建、分析和建模已被用于包括黑色素瘤在内的不同恶性肿瘤,以分析和整合“组学”数据、制定肿瘤发生的机制假说、评估和个性化抗癌治疗,并提出新的药物靶点。在此,我们综述了癌症网络建模方法的当前知识,特别强调黑色素瘤。

相似文献

1
Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers.黑色素瘤及其他癌症中蛋白激酶信号通路的建模
Cancers (Basel). 2019 Apr 3;11(4):465. doi: 10.3390/cancers11040465.
2
Atypical and Mutations in Mucosal Melanoma.黏膜黑色素瘤中的非典型性和突变
Cancers (Basel). 2019 Aug 8;11(8):1133. doi: 10.3390/cancers11081133.
3
Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.皮肤黑色素瘤中的丝裂原活化蛋白激酶信号通路:最新综述
Arch Pathol Lab Med. 2016 Nov;140(11):1290-1296. doi: 10.5858/arpa.2015-0475-RS.
4
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.BRAF 突变型结直肠癌中通过 MAPK 通路改变对 RAF 抑制剂联合治疗产生临床获得性耐药
Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.
5
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives.BRAF抑制剂在甲状腺癌中的应用:临床影响、耐药机制及未来展望
Cancers (Basel). 2019 Sep 18;11(9):1388. doi: 10.3390/cancers11091388.
6
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.针对人类癌症中致癌性 Raf 蛋白-丝氨酸/苏氨酸激酶。
Pharmacol Res. 2018 Sep;135:239-258. doi: 10.1016/j.phrs.2018.08.013. Epub 2018 Aug 15.
7
BRAF, a target in melanoma: implications for solid tumor drug development.BRAF,黑色素瘤的靶点:对实体瘤药物开发的影响。
Cancer. 2010 Nov 1;116(21):4902-13. doi: 10.1002/cncr.25261.
8
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.黑色素瘤中获得性BRAF抑制剂耐药机制:一项系统综述
Cancers (Basel). 2020 Sep 29;12(10):2801. doi: 10.3390/cancers12102801.
9
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.MAPK 信号的过度激活对 RAS/RAF 突变型黑色素瘤有害。
Mol Cancer Res. 2019 Jan;17(1):199-211. doi: 10.1158/1541-7786.MCR-18-0327. Epub 2018 Sep 10.
10
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.转移性黑色素瘤患者对威罗菲尼耐药的药效学作用和机制。
J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8.

引用本文的文献

1
Mathematical Modeling and Inference of Epidermal Growth Factor-Induced Mitogen-Activated Protein Kinase Cell Signaling Pathways.表皮生长因子诱导的丝裂原激活蛋白激酶细胞信号通路的数学建模与推断。
Int J Mol Sci. 2024 Sep 23;25(18):10204. doi: 10.3390/ijms251810204.
2
CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.嵌合抗原受体自然杀伤(CAR-NK)细胞疗法治疗转移性黑色素瘤:潜力与展望。
Cells. 2023 Nov 30;12(23):2750. doi: 10.3390/cells12232750.
3
Minerals and Cancer: Overview of the Possible Diagnostic Value.

本文引用的文献

1
Receptor Tyrosine Kinase-Targeted Cancer Therapy.受体酪氨酸激酶靶向癌症治疗。
Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491.
2
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.癌症免疫治疗的范式转变:从增强到正常化。
Cell. 2018 Oct 4;175(2):313-326. doi: 10.1016/j.cell.2018.09.035.
3
Melanoma.黑色素瘤。
矿物质与癌症:潜在诊断价值概述
Cancers (Basel). 2022 Feb 28;14(5):1256. doi: 10.3390/cancers14051256.
4
Hyperphosphorylation of HDAC2 promotes drug resistance in a novel dual drug resistant mouse melanoma cell line model: an study.HDAC2的过度磷酸化在一种新型双耐药小鼠黑色素瘤细胞系模型中促进耐药性:一项研究。
Am J Cancer Res. 2021 Dec 15;11(12):5881-5901. eCollection 2021.
5
Interaction of Glia Cells with Glioblastoma and Melanoma Cells under the Influence of Phytocannabinoids.植物大麻素影响下神经胶质细胞与胶质母细胞瘤及黑色素瘤细胞的相互作用
Cells. 2022 Jan 3;11(1):147. doi: 10.3390/cells11010147.
6
Mitochondrial Metabolism in Melanoma.黑色素瘤中的线粒体代谢。
Cells. 2021 Nov 16;10(11):3197. doi: 10.3390/cells10113197.
7
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.在接受检查点抑制剂治疗后,BRAF 突变转移性黑色素瘤初始进展时谨慎地添加靶向治疗联合 PD-1 抑制剂。
BMC Cancer. 2021 Nov 7;21(1):1187. doi: 10.1186/s12885-021-08906-1.
8
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era.转移性黑色素瘤细胞学样本的预测性评估:BRAF免疫细胞化学在分子时代的作用。
Diagnostics (Basel). 2021 Jun 18;11(6):1110. doi: 10.3390/diagnostics11061110.
9
Higher Mutation Burden in High Proliferation Compartments of Heterogeneous Melanoma Tumors.异质性黑色素瘤肿瘤高增殖区的更高突变负担。
Int J Mol Sci. 2021 Apr 9;22(8):3886. doi: 10.3390/ijms22083886.
10
Biomarker-guided heterogeneity analysis of genetic regulations via multivariate sparse fusion.基于多元稀疏融合的遗传调控标志物指导异质性分析。
Stat Med. 2021 Jul 30;40(17):3915-3936. doi: 10.1002/sim.9006. Epub 2021 Apr 27.
Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9.
4
Rates of Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an -Amplified Acral Melanoma.在一个扩增的肢端黑色素瘤中,黑色素瘤亚型的改变率和曲妥珠单抗-美坦新偶联物的完全缓解率。
Clin Cancer Res. 2018 Dec 1;24(23):5815-5819. doi: 10.1158/1078-0432.CCR-18-1397. Epub 2018 Aug 9.
5
Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.基于结构建模解析 RAF 抑制剂耐药性揭示克服致癌 RAS 信号的方法。
Cell Syst. 2018 Aug 22;7(2):161-179.e14. doi: 10.1016/j.cels.2018.06.002. Epub 2018 Jul 11.
6
RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.RNA-seq 分析鉴定了原发性黑色素瘤的不同转录组类型和发育轨迹。
Oncogene. 2018 Nov;37(47):6136-6151. doi: 10.1038/s41388-018-0385-y. Epub 2018 Jul 11.
7
Patterns of genomic evolution in advanced melanoma.晚期黑色素瘤中的基因组进化模式。
Nat Commun. 2018 Jul 10;9(1):2665. doi: 10.1038/s41467-018-05063-1.
8
The promise and challenges of immune agonist antibody development in cancer.免疫激动剂抗体在癌症中的前景与挑战。
Nat Rev Drug Discov. 2018 Jul;17(7):509-527. doi: 10.1038/nrd.2018.75. Epub 2018 Jun 15.
9
Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.恶性黑色素瘤中丝裂原活化蛋白激酶抑制剂耐药性的系统生物学分析
BMC Syst Biol. 2018 Apr 4;12(1):33. doi: 10.1186/s12918-018-0554-1.
10
Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.细胞信号异质性受细胞内和细胞外机制的调节:一种综合方法来理解靶向治疗。
PLoS Biol. 2018 Mar 9;16(3):e2002930. doi: 10.1371/journal.pbio.2002930. eCollection 2018 Mar.